Shreya Sengupta

Shreya Sengupta

Auto-generated profile, based on publicly available information

Shreya Sengupta

Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in Hepatology Communications
Verified
Journal Article
Open access
SSShreya Sengupta
Shreya Sengupta
AAAkhil Anand
Akhil Anand
QYQijun Yang
Qijun Yang
MRMeghan Reagan
Meghan Reagan
MHMariah Husted
Mariah Husted
JMJessica L. Mellinger
Jessica L. Mellinger
Background: We analyzed early outcomes regarding the impact of our integrated alcohol-associated liver disease (ALD) clinic on patients with ALD and alcohol use. Methods: We conducted a retrospective study of patients with ALD who were evaluated in our integrated clinic from May 1, 2022, to December 31, 2023. Primary outcomes included differences in baseline clinical/demographic data between patients who accepted versus declined an appointment and changes in the severity of ALD, alcohol consumption, functional status, hospital utilization, and remission in alcohol use disorder for evaluated patients. Results: Patients who declined appointments (n=66) had higher median no-show rates (15.0 [8.0,30.0] vs. 8.5 [3.25,15.0], p <0.001), social vulnerability index (0.53 [0.26,0.79] vs. 0.38 [0.17,0.63], p =0.033), and proportions of cirrhosis (78.8% vs. 59.8%, p =0.017) versus evaluated patients. Comparison of baseline to first follow-up visit for evaluated patients (n=102) demonstrated significant reductions in median AST (59.5 [41.75, 89] vs. 44.5 [33.5, 56.25], p <0.001), alanine-aminotransferase (33.5 [20,45.25] vs. 26.5 [18.75,33.0], p =0.017), total bilirubin (1.6 [0.7,3.3] vs. 1 [0.5,1.9], p= 0.001), phosphatidylethanol (263 [35, 784] vs. 0 [0, 163], p <0.001), MELD-3.0 and Sodium scores for patients with alcohol-associated hepatitis and cirrhosis (16 [11, 18.75] vs. 12 [9, 14], p <0.001), 14 [9.25, 17.75] vs. 11 [8.5, 14], p <0.001), and Child-Turcotte-Pugh scores for patients with cirrhosis (9 [6, 10.5] vs. 7 [6, 9], p <0.001). The proportion of patients with active-severe alcohol use disorder significantly decreased (85.2% vs. 51.9%, p <0.001). Additionally, patients had significant reductions in emergency department utilization (incidence rate ratio of 0.64 emergency department visits/month ( p =0.002) and 0.71 hospital admissions/month ( p =0.025). However, after considering the false discovery rate, the reduction in hospitalization admissions/month was not statistically significant (False Discovery Rate adjusted p =0.056). Conclusions: Our integrated approach led to reductions in liver injury, degree of liver decompensation, alcohol use, and ED utilization, and remission in AUD in a population of both non-transplant ALD and post-transplant patients.

1 September 2023 in ACG Case Reports Journal
Verified
Journal Article
Open access
BEBaila Elkin
Baila Elkin
DADaniela S. Allende
Daniela S. Allende
SSShreya Sengupta
Shreya Sengupta
Liver transplant is a rare phenomenon for pyruvate kinase deficiency (PKD)-related liver disease and can be mediated by multiple mechanisms. In this report, we present a 55-year-old man with PKD who had acute-on-chronic liver failure with kidney failure and marked hyperbilirubinemia. His liver disease was from recurrent cholangitis, cholestasis from hemolysis, and iron deposition (likely from both repeated transfusions in youth and chronic hemolysis), all consequences of his PKD. He received a liver transplant and had a good outcome. Our case highlights the mechanisms of liver injury in PKD and successful transplantation for this rare complication.

1 January 2024 in Clinical Liver Disease
Verified
Journal Article
Closed access
SSShreya Sengupta
Shreya Sengupta
JMJessica L. Mellinger
Jessica L. Mellinger

25 April 2025 in ACG Case Reports Journal
Verified
Journal Article
Open access
RPRenan Prado
Renan Prado
ACArjun Chatterjee
Arjun Chatterjee
ZZZurabi Zaalishvili
Zurabi Zaalishvili
RKRupayan Kundu
Rupayan Kundu
SJShilpa Junna
Shilpa Junna
SMSyed A. Mohiuddin
Syed A. Mohiuddin
Tacrolimus-induced acute pancreatitis (TAP) is rare and requires thorough evaluation, including genetic testing, to rule out other causes. While TAP has been documented in a few cases following kidney transplantation, we report the first case of TAP in an adult after liver transplantation, with a noteworthy feature of late-onset TAP occurring more than 12 months after initiating tacrolimus therapy. This case highlights the potential for delayed onset of TAP, and we suggest that tacrolimus may warrant reclassification from category III to Ic in the drug-induced pancreatitis classification. In addition, we introduce sirolimus as a viable alternative for immunosuppression following TAP.

22 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MAMohamamd ALABBAS
Mohamamd ALABBAS
JSJingyi Shi
Jingyi Shi
YGYuqi Guo
Yuqi Guo
HWHongke Wu
Hongke Wu
IOIbukunoluwa Oshobu
Ibukunoluwa Oshobu
OSOmar T Sims
Omar T Sims
Background: Smoking in patients with hepatitis C (HCV) amplifies the risk of cirrhosis and hepatocellular carcinoma. We aimed to estimate the prevalence of active smoking over the last decade at the population level among adults living with HCV in the U.S., estimate temporal trends in active smoking, and identify factors associated with active smoking. Methods: We analyzed repeated cross-sectional NHANES data (2007–2018) of adults ≥20 years old with serologic evidence of HCV and complete smoking data (unweighted [n = 621] and weighted [n = 3,620,603] sample size). Temporal trends were evaluated using linear regression and joinpoint regression. Survey-weighted multivariable logistic regression was used to identify factors associated with active smoking. Results: The cumulative prevalence of active smoking was 56.4% (95% CI, 49.2–63.4). Linear trend testing was not significant (p = 0.93). Joinpoint regression suggested a slope change near 2013–2014, but neither segment-specific annual percent changes nor the slope change reached significance. Factors associated with higher odds of active smoking included female sex (aOR = 2.23; 95% CI, 1.17–4.24), low poverty income ratio (aOR = 3.33; 1.41–7.84), lifetime substance use (aOR = 10.63; 3.08–36.70), and depression (aOR = 2.65; 1.29–5.45). Lower odds were observed with >high-school education (aOR = 0.50; 0.26–0.94), obesity (aOR = 0.32; 0.18–0.58), and ≥2 yearly healthcare visits (aOR = 0.27; 0.10–0.68). Conclusions: Smoking appears to be endemic within the HCV population, and rates have remained alarmingly high and stagnant (i.e., unchanged or have not decreased) over the last decade, which consequently can lead to heightened incident cases of HCV-related cirrhosis and hepatocellular carcinoma in the near future.

13 August 2024 in Liver Transplantation
Verified
Journal Article
Closed access
SSShreya Sengupta
Shreya Sengupta
JMJessica L. Mellinger
Jessica L. Mellinger
An abstract is unavailable. This article is available as a PDF only.